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Abstract 
A clinical study was conducted to assess the ability of commercially 
available immunoassays to detect flunitrazepam (FNP) in plasma 
and urine samples and to compare the results with those obtained 
by gas chromatography-mass spectrometry (GC-MS). The clinical 
study consisted of four individuals (two male and two female) who 
had taken a single 2-rag dose of FNP. Serum was collected over a 
48-h period and urine was collected over a 72-h period. The serum 
and urine samples were analyzed by the COBAS | INTEGRA Serum 
Benzodiazepines assay (SBENZ), the TDx serum and urine 
Benzodiazepines assay, and GC-MS. The GC-MS procedure was 
developed for analysis of FNP and metabolites in plasma and urine 
using an acid hydrolysis step resulting in the formation of specific 
benzophenones corresponding to FNP and its metabolites. The 
relative sensitivities of the assays for the detection of FNP and 
metabolites in serum and urine were GC-MS > SBFNZ > TDx. 
The immunoassay results for serum samples showed peak 
concentrations of FNP metabolites at 8 h after FNP ingestion for 
three individuals and at about I h for the fourth individual. The 
GC-MS, SBENZ, and TDx urine immunoassays detected drug above 
the stated limit of detection (LOD) in 44, 41, and 35 serial FNP 
urine samples, respectively. FNP metabolites were detected in urine 
samples with all three assays for up to 72 h after a 2-mg dose. The 
improved detection rate with the SBENZ assay as compared to the 
TDx assay is likely explained by its higher cross-reactivity with the 
major metabolite, 7-amino-flunitrazepam (7-amino-FNP), and its 
lower LOD. 
Introduction 
Rohypnol | or flunitrazepam (FNP) is a fluorinated derivative 
of the benzodiazepine series. Rohypnol is not legally available 
in the United States, even for medical purposes, but it is an ap- 
proved medication for sleep disorders in other parts of the 
world. Rohypnol has various street names, Rochies, Rophies, 
Roofies, and has been implicated in cases involving sexual as- 
sault. Rohypnol produces sedative effects; induces muscle re- 
laxation and memory loss; decreases inhibitions; and impairs 
judgment, motor skills, and memory. Sedation occurs 20 to 30 
min after administration of a 2-mg tablet and lasts for several 
hours thereafter. There are recent reports of increased abuse 
and illegal diversion of the drug into the U.S. (1). Flunitrazepam 
belongs to the potent group of benzodiazepines, which are 
therapeutically effective at low doses, making its detection 
more difficult. It is therefore important to select an im- 
munoassay screening method that has the ability to detect low 
doses of this newly abused hypnotic drug. There have recently 
been new gas chromatography-mass spectrometry (GC-MS) 
methods developed for the detection of FNP and its metabolites 
in urine (2) and in whole blood or plasma (3). In addition there 
is a description of FNP excretion patterns in urine comparing 
the Abuscreen OnTrak and OnLine Immunoassays to GC-MS 
(4). In that study, urine samples collected following ingestion 
of a 4-rag dose of FNP did yield positive results in both the On- 
Line and OnTrak assays for at least 32 h after ingestion. After a 
1-mg dose, positive specimens were detected only by GC-MS, 
but not by immunoassay. 
The detection of FNP abuse in urine samples between i to 16 
h postingestion of low doses of the drug requires the selection 
of an immunoassay with good cross-reactivity to FNP metaboli- 
tites. This is illustrated in a most recent study (5) where an an- 
tibody was generated that had very high cross-reactivity to 
7-amino-FNP allowing its detection following ingestion of 
0.5 mg FNP. 
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Although there are controlled studies using GC-MS methods 
to detect positive specimens in whole blood, plasma, and urine 
(2,3), there are no available studies evaluating commercial im- 
munoassays for the automated detection of FNP and metabo- 
lites in a blood component and urine collected in parallel from 
the same subject. 
This study was conducted to compare two immunoassays, 
SBENZ and TDx, with GC-MS for the detection of FNP and 
metabolites in serum and urine following ingestion of a 2-rag 
dose of FNP. 
Experimental 
Biological samples 
The flunitrazepam clinical study was approved by the Ethics 
Committee Faculty of Medicine at the University of Bern. All 
subjects that participated in the study were volunteers, naive to 
the drug, and supplied informed consent. Two healthy male 
subjects (27 years, 62 kg in weight, smoker and 28 years, 82 kg 
in weight, non-smoker) and two healthy female subjects (both 
29 years old, 55 kg in weight, and non-smokers) participated in 
the study. A single oral dose of 2 mg of FNP was ingested. 
Blood samples were collected before ingestion of FNP and at 1, 
2, 4, 6, 8, 12, 15, 24, 36, and 48 h after ingestion. Blood was al- 
lowed to clot, and then serum was collected by centrifugation. 
All specimens from the study were frozen at-24~ within 12 h 
to eliminate any issue of sample instability. Urine samples were 
collected, and the volumes were measured before ingestion 
and then at 2, 4, 8, 12, 18, 24, 36, 48, 60, and 72 h after inges- 
tion. Urine specimens were accurately timed and collected in 
polypropylene bottles without additives and immediately re- 
frigerated. All specimens from the study were frozen at -24~ 
within 12 h of collection. 
Materials 
FNP, 7-amino-FNP, desmethylflunitrazepam (nor-FNP), and 
7-amino-nor-FNP were supplied by Hoffmann-LaRoche (Nutley, 
N J). 7-Amino-FNP-d3 was purchased from Lipomed, Inc. (Cam- 
bridge, MA). TDx Benzodiazepines Serum reagents, limit of 
detection (LOD) 12 ng/mL, and calibrators and TDx Benzodi- 
azepines U reagents, LOD 40 ng/mL, and calibrators were pur- 
chased from Abbott Diagnostics Division (North Chicago, IL) 
and used according to the manufacturer's package insert direc- 
tions. 
The SBENZ assay for the analysis of benzodiazepines in 
serum and urine, from Roche Diagnostic Systems, uses fluor- 
escence polarization (FPIA) technology and was run on the 
COBAS INTEGRA analyzer. Calibration of the SBENZ urine 
and serum assays was performed using the Abuscreen OnLine 
Serum Benzodiazepine calibrators from Roche Diagnostic Sys- 
tems and the Lypochek Benzo/TCA Control-Set B from Bio-Rad, 
(Anaheim, CA). The LOD for this assay was stated to be 3 ng/mL 
for serum and 7 ng/mL for urine. 
Immunoassay analysis 
The COBAS INTEGRA from Roche Diagnostic Systems, 
(Basel, Switzerland) and the TDx analyzer from Abbott Diag- 
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nostics (North Chicago, IL) were used according to the manu- 
facturer's instructions. 
GC-MS analysis 
GC-MS analysis of FNP and metabolites in urine was per- 
formed using a recently published procedure with a reported 
LOD of I ng/mL (2), except that 7-amino-FNP-d3 was used as 
internal standard. GC-MS analysis of FNP and metabolites in 
serum was performed for the total 7-amino metabolites using 
acid hydrolysis procedure as well as for the free 7-amino 
metabolite using direct extraction and analysis. 
GC--MS procedure for analysis of total 7-amino-FNP metabo- 
lites. To 1 mL of serum sample was added 50 IJL of 7-amino- 
FNP-d3 at 1 IJg/mL (50 ng/mL of serum concentration). Three 
milliliters of methanol was added and the sample was vigorously 
vortex mixed for 2 min. The sample was then centrifuged at 3000 
rpm for 5 min. The supernatant was poured into a 15-mL tube, 
and the precipitate was discarded. The methanol was evapo- 
rated to a volume of less than 0.5 mL under a stream of N2 at 
50~ Two milliliters of deionized (DI) water and I mL of con- 
centrated HC1 were added. The tube was tightly capped and 
placed in an oven at 100~ for I h. After the tube was taken out 
of the oven and cooled to room temperature, 1.5 mL of 10N 
KOH was added and the sample was vortex mixed. Six milliliters 
of chloroform was added, and the sample was shaken gently for 
2 min. After the sample separated into two layers (centrifugation 
may be needed to help phase separation), the top aqueous layer 
was aspirated to waste. The chloroform layer was washed with 1 
mL of DI water and then poured into a 13 • 100-ram test tube. 
The solvent was evaporated under N2 at 50~ in a water bath. 
The residue was dissolved in 0.5 mL of chloroform containing 20 
tJg/mL of 4-pyrrolidinopyridine, and 100 lJL of heptafluorobu- 
tyric anhydride was added. The sample was vortex mixed and al- 
lowed to stand at room temperature (65-75~ for I h before the 
addition of 0.2 mL of 2N NaOH and 1 mL of 1.5M carbonate 
buffer (pH 11). After vortex mixing for 30 s, the aqueous layer 
was aspirated to waste. One milliliter of DI water was added, and 
the sample was vortex mixed for 30 s. The organic layer was then 
transferred to a GC vial, and the solvent was evaporated under 
N2 at 50~ The residue was dissolved in 70 mL of ethyl acetate 
for GC-MS analysis. Two microliters of sample was injected. 
This described procedure is a modification of the recently pub- 
lished GC-MS procedure for whole blood and plasma (3). 
A Hewlett-Packard (Palo Alto, CA) 5890 GC interfaced with a 
Hewlett-Packard 5970 MSD was used. The electron multiplier 
voltage was set at 200 V above the tune value. The GC was 
equipped with a 25-m • 0.2-mm (0.33-1Jm film thickness) DB- 
5 MS column operated in the splitless mode with purge valve 
closed for 0.2 min. Helium carrier flow was 43 cm/min. Oven 
temperature was set at 180~ held for 0.5 rain, then increased 
to 260~ at 20~ where it was held for 1 rain, then finally 
increased to 280~ at 30~ and held for 8 rain. The injector 
and detector temperatures were 250 and 280~ respectively. A 
Hewlett-Packard G1034C version C.02.00 ChemStation data 
system was used to record the data. SIM ions for the various an- 
alytes were as follows (quantitation ions are underlined): 516 and 
639 for 7-amino-FNP-d3 (Rt = 5.70 rain); 513, 636, and 439 for 
7-amino-FNP (Rt = 5.71 min); 274 and 257 for flunitrazepam 
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Table I. Concentration of Total 7-Amino-FNP and Free 
7-Amino-FNP in Serum Collected from Four Subjects 
Administered a Single 2-rag Oral Dose 
GC-MS conc. (ng/mt) TDx SBENZ 
Subject Time after Total 7- Free 7- conc. conc. 
sample ingestion (h) NH2-FNP NH2-FNP (ng/mL) (ng/mL) 
A 0 0 0 0 0 
A 0,5 0 0 0 0 
A 1 0.8* 0.25 0 0 
A 2 3.6 1.4 0 0 
A 4 7.0 3.2 0 0 
A 6 12.5 5.9 0 5.3 
A 8 11.6 5.0 0 5.4 
A 12 11.6 4.4 0 3.3 
A 16 13.5 4.1 0 0 
A 24 17.5 5.3 0 0 
A 36 11.3 3.4 0 0 
A 48 8.6 2.7 0 0 
B 0 0 0 0 0 
B 0.5 3.1 0.95 0 4.1 
B I 4.6 2.0 0 6.7 
B 2 9.8 4,1 16.5 8.5 
B 4 10.6 5.7 0 4.4 
B 6 ND t 4.1 0 0 
B 8 12.7 4.3 0 13 
B 12 10.9 5.0 0 9.5 
B 16 10.8 3.6 0 0 
B 24 ND * 3.9 0 0 
B 36 7.3 2.9 0 0 
B 48 5.0 2 0 0 
C 0 0 0 0 0 
C 0.5 0 0 0 0 
C l 3.1 1.5 0 0 
C 2 6.1 2.3 0 0 
C 4 10.3 4.1 0 5.6 
C 6 9.7 4,0 0 4.6 
C 8 4.5 3.6 0 12,2 
C 12 7.0 3.9 0 0 
C 16 6.1 3.6 0 0 
C 24 7.7 3.7 0 0 
C 36 6.0 2.7 0 0 
C 48 4.0 2.3 0 0 
D 0 0 0 0 0 
D 0.5 0.9 0 0 0 
D 1 ND t 2.1 0 5 
D 2 4.7 3.3 0 0 
D 4 5.9 5.8 0 3.3 
D 6 5.2 6.2 0 0 
D 8 5.5 5.5 0 0 
D 12 5.8 5.8 0 0 
D 16 5.6 4.8 0 0 
D 24 4.5 4.3 0 0 
D 36 4.5 3.8 0 0 
D 48 7.2 2.4 0 0 
* Lower than established LOD but quantitated because these samples showed 
acceptable ion ratios. 
Not detected, possibly because of the low extraction recovery evidenced by low 
intensity of the internal standard peak; insufficient sample to reanalyze. 
(Rt = 7.56 rain); 453, 622, and 499 for 7-amino-nor-FNP (Rt = 
5.32 rain); and 45__66 and 333 for nor-FNP (Rt = 5.55 rain). 
Extraction and GC-MS procedure for analysis of free 7- 
arnino-FNP in serum. To I mL of serum was spiked 10 laL of 7- 
amino-FNP-d3 at 1 l~g/mL. Four milliliters of methanol was 
added, and the sample was vigorously vortex mixed for 2 rain. 
Then it was centrifuged at 3000 rpm for 5 min, and the super- 
natant was evaporated to about 0.5 mL. One milliliter of 40% 
phosphate buffer (pH 9.0) and 4 mL of ethyl acetate were added, 
the sample was shaken for 2 min, and the aqueous layer was dis- 
carded. The organic layer was shaken with I mL of 1N HC1 for 
2 rain and the organic layer was discarded. To the aqueous 
layer, was added 0.7 mL of 2N NaOH and 3 mL of ethyl acetate. 
The sample was shaken for 2 min. The organic layer was evap- 
orated under N~ at 50~ The residue was dissolved in 0.5 mL 
of CHCI3 containing 20 lag/mL of 4-pyrolidinopyridine, and 
100 laL of heptafluorobutyric anhydride was added. The sample 
was vortex mixed and allowed to stand at room temperature for 
I h before the addition of 0.2 mL of2N NaOH and I mL of 1.5M 
carbonate buffer (pH 11). After vortex mixing for 1 rain, the 
aqueous layer was aspirated and discarded. The organic layer 
was washed with I mL of DI water and then transferred into a 
GC vial. The solvent was evaporated under N2 at 50~ and the 
residue was reconstituted with 50 lJL of ethyl acetate. Two mi- 
croliters of sample was injected. GC-MS conditions were as 
follows: The oven temperature was programmed at 200~ held 
for 0.5 rain, then raised to 270~ at 30~ where it was held 
for 6.5 rain. A splitless injector was used with purge valve 
closed for 0.6 rain. The electron multiplier voltage was set at 
600 V above the tune value. The retention time for 7-amino- 
FNP-d3 and 7-amino-FNP were 8.51 and 8.54 min, respectively. 
The SIM ions were 45___44 and 482 for 7-amino-FNP-d3 and 451, 
479, and 460 for 7-amino-FNP. 
Results 
Both physical drug effects and analytical drug excretion results 
for this study were recorded. A 2-rag dose of flunitrazepam had 
various effects on the four subjects as based on both self- 
reporting by the individuals and independent observation by 
one of the authors. Physiological measurements were not made. 
Subject A became somewhat drowsy at I h, but exhibited no 
problem with speaking, orientation, or coordination. He was in 
a deep sleep at 2 h, experienced intense hunger at 4 to 6 h, and 
was completely recovered at 12 h. Subject B exhibited a loss of 
coordination and fell into a deep sleep at i h. Decreased coordi- 
nation remained at 4 h accompanied by signs of amnesia and dif- 
ficulty in speaking. He recovered by 12 h except for the persistent 
amnesia. Subject C experienced great fatigue at 1 h. At 4 h she 
was still very tired and had orientation and speaking problems 
with evidence of some amnesia. At 12 h, she was still tired, but 
the other side effects were gone. Subject D became euphoric and 
experienced slight vertigo at I h. At about I h, 20 rain, she re- 
ported being very tired. At 2 h, subject D was completely recov- 
ered, and at 4 h she was alert showing no residual effects. 
GC-MS analysis of the serum samples was carried out 
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Table II. Concentration of FNP and Metabolites in Urine 
Collected From Four Subjects Administered a Single 
2-mg Oral Dose 
GC-MS conc. (ng/mt) TDx SBENZ 
Subject Time after 7-amino-7-amino- conc. conc. 
sample ingestion(h) FNP NOR-FNP FNP (ng/mL) (ng/mt) 
A 0 0 0 0 46.6 < LOD 
A 2 27.4 5 0 0 < LOD 
A 4 45.4 3 0 0 9.3 
A 8 218.7 27.2 0 74.2 69.7 
A 12 276.4 39.7 36.5 97.6 112.6 
A 18 127.7 25 17.7 52.2 52.7 
A 24 101.1 25.2 0 44.2 48.5 
A 30 83.6 25 0 49.6 39.2 
A 36 72.9 29.6 0 0 24.8 
A 48 126.3 60.6 0 59.3 52.9 
A 60 61.4 40.9 0 48.9 28.1 
A 72 100.6 77.3 0 60.3 52.4 
B 0 0 0 0 0 < LOD 
8 2 142.4 11.7 35.1 0 14.4 
B 4 160.6 9.3 36.1 43.2 41.6 
B 8 309.8 23.9 48 98.1 141.9 
B 12 423.2 48.3 62.8 103.2 174.2 
B 18 463.5 80.3 0 109.3 179.4 
B 24 332.2 47.1 0 78 134.7 
8 30 177.3 33.1 0 42.6 35.2 
B 36 343.3 77.6 0 97.2 95.2 
8 48 89.6 20.6 0 75.2 58 
B 60 93.4 33.3 0 40.3 18.6 
B 72 109.6 53.1 0 68.9 47.7 
C 0 0 0 0 0 < LOD 
C 2 47.7 0 0 59.4 11.5 
C 4 40.0 1.0 32.0 0 11.8 
C 8 226.2 26.0 73.5 74.6 83.2 
C 12 279.5 54.5 112.5 84 110 
C 18 98.9 22.0 54.0 46 40.8 
C 24 138 40.5 0 56.7 62.7 
C 30 57.9 18.1 0 0 19.3 
C 36 74.8 32.6 0 52 23.5 
C 48 53.2 30.2 0 43.9 26 
C 60 81 53.1 0 46.6 42 
C 72 36.2 37.4 0 46.8 20.8 
D 0 0 0 0 0 < LOD 
D 2 19.4 0 0 0 7.3 
D 4 69.7 4.1 0 0 11.7 
D 8 89.6 3.3 18 0 21.3 
D 12 174.9 24.4 53.7 61.3 66,5 
D 18 231.5 34.3 20.1 69.8 84.5 
D 24 157,8 22.9 0 53.9 48 
D 30 175.7 32.9 0 72.2 59 
D 36 298.6 101.2 0 98.5 139.6 
D 48 139.4 43.7 0 65.8 51.9 
D 60 122.3 57.2 0 77.6 59.2 
D 72 82.3 34.2 0 56.9 35.7 
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by two procedures. First an acid hydrolysis procedure that 
converts all metabolites to a single common benzophenone 
was utilized. For example, 7-amino-FNP, 7-acetamido-FNP, 
7-NH2-3-OH-FNP, and its glucuronide are all converted to 
the same benzophenone upon acid hydrolysis. Similarly, FNP, 
3-OH-FNP, and its glucuronide are converted to the same 
benzophenone. The LOD (determined as the lowest concen- 
tration of each analyte that provided a signal-to-noise ratio 
greater than 5 for the quantitation ion with acceptable ion 
ratios), limit of quantitation (LOQ, determined as the lowest 
concentration at which all acceptance criteria were met, in- 
cluding quantitation values within + 20% of the target con- 
centration), and linearity were determined. The LODs for 
7-amino-FNP and FNP were 3 ng/mL and 10 ng/mL, respec- 
tively. The LOQ for each analyte was the same as the LOD. 
Other metabolites were not spiked and all curves were linear up 
to 200 ng/mL. 
Second, because only 7-amino-FNP was detected during the 
analysis of the total metabolites, analysis of the serum samples 
was also carried out for the free 7-amino-FNP. A liquid-liquid 
extraction procedure, which employed a back-extraction step, 
was used to clean up the sample extracts prior to derivatization. 
Similarly, with this procedure, the LOD, LOQ, and linearity 
were determined. The LOD and LOQ were both at 1 ng/mL 
(lowest concentration tested), and the calibration curve was 
linear from i to 50 ng/mL, the latter being the highest con- 
centration tested. The extraction recovery of the free 7-amino- 
FNP was 96% at 1 ng/mL. This was determined by comparing 
the peak area from the extracted serum sample spiked with 7- 
amino-FNP to the peak area of 7-amino-FNP in the unextracted 
sample at the same concentration. 
The results obtained with the GC-MS method for the detec- 
tion of total FNP and 7-amino-FNP in serum were similar to 
those previously reported for whole blood and plasma (3). 7- 
Amino-FNP was detected as early as 0.5 h following drug in- 
gestion and throughout the collection period (48 h), but the 
parent compound, FNP, as well as 7-amino-nor-FNP and nor- 
FNP were not detected in the samples. Table I shows the 
GC-MS analysis values for the total 7-amino-FNP in the indi- 
vidual samples collected from four subjects. The table also 
shows the values for the free 7-amino-FNR It is clear that for 
the majority of the samples the amount of the total 7-amino- 
FNP was 2-3 times that of the free 7-amino-FNP, except for sub- 
ject D for whom the values of the total and free were very close 
up to the 36-h collection time. 
As shown in Table I, the immunoassays (primarily the SBENZ 
assay) detected cross-reacting benzodiazepines in serum 
between 0.5 and 12 h after ingestion of a 2-mg dose of FNP 
with the concentration values for the SBENZ assay ranging 
from 3.3 to 13.0 ng/mL. This assay had a reported LOD of 
3 ng/mL and cross-reactivities of 60.8% for 7-amino-FNP, 38% 
for 7-amino-nor-FNP, and 48% for nor-FNP relative to nor- 
diazepam at 100-ng/mL cutoff level (Roche Diagnostic Corp. 
Package Insert). 
Only one sample tested positive by TDx. This assay had a re- 
ported 12 ng/mL LOD and 15% cross-reactivity to the major 
metabolite, 7-amino-FNP (Abbott Labs. Package Insert). 
The SBENZ immunoassay showed serum peak concentra- 
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tions between 7 and 8 h for 3 individuals and I h for the fourth 
individual, with the maximum concentration being 13.0 ng/mL. 
Peak concentrations by GC-MS for the free 7-amino-FNP oc- 
curred at 4 or 6 h with a maximum value of 6.2 ng/mL. The 
peak value for total amount of metabolites calculated as 7- 
amino-FNP, however, was much more variable, occurring be- 
tween 4 and 48 h and ranging from 7.2 to 17.5 ng/mL. The 
immunoassays detected up to 13 (38%) of the 37 samples con- 
sidered positive by GC-MS (Table I). 
FNP, noroFNP, and 7-amino-FNP above the LOD of the 
GC-MS method were found in urine (Table II). Although the 
quantitative values for the immunoassays were generally lower 
than with the GC-MS assay, very similar excretion patterns 
were observed for all three methods (Figure 1). In addition all 
methods produced positive results throughout the entire 72 h 
collection period. The SBENZ and TDx assays detected 43 (98%) 
and 36 (82%) samples, respectively, above their stated LOD 
values. These samples were considered positive relative to the 
GC-MS results. 
Discussion 
Serum immunoassays are commonly used in emergency 
room settings to identify expected ingested substances and 
subsequently treat patients. Urine assays are commonly used to 
determine past exposure to a drug. In the case of serum, the 
SBENZ assay exhibited much better sensitivity than the TDx 
assay for the detection of the presence of FNP and metabo- 
lites, but only identified 14 (38%) of the 37 GC-MS-positive 
samples. The better detection rate of the SBENZ assay in com- 
parison to the TDx assay is likely due to the lower LOD and the 
higher cross-reactivity to 7-amino-FNP of the SBENZ assay. The 
lower values observed with the immunoassays when compared 
to GC-MS for serum samples is mainly attributed to the lower 
level of FNP metabolites in serum coupIed with the low cross- 
reactivity of the assay antibody to 7-amino-FNP. The GC-MS 
methods with better sensitivity and discriminatory power pro- 
vide more reliable quantitative values. 
The excellent correlation of excretion patterns obtained by 
immunoassay and GC-MS with the urine samples is shown in 
Figure I and attributed to the more reliable immunoassay re- 
sults obtained with these samples that contain significantly 
more measureable FNP metabolites than those found in the 
serum samples. The much higher GC-MS values are attributed 
to the fact that acid hydrolysis converts all metabolites sharing 
the same basic nucleus to one common benzophenone. For ex- 
ample, 7-amino-FNP, 7-amino-3-OH-FNP, and its glucuronide 
as well as 7-acetamido-FNP, 7-acetamido-3-OH-FNP, and its 
glucuronide would all be converted to one common ben- 
zophenone characteristic for 7-amino-FNP. If only one metabo- 
lite is to be monitored by GC-MS, 7-amino-FNP, the 
predominant metabolite detected, should be selected. 
Conclusions 
This report provides a controlled study comparing im- 
munoassays to GC-MS for the detection of FNP ingestion. 
Serum and urine samples collected from the same subjects 
following ingestion of 2 mg FNP were evaluated. GC-MS de- 
tected the presence of only 7-amino-FNP in serum. 7-Amino- 
FNP was the predominant metabolite in urine, but 
7-amino-nor-FNP and FNP were also detected with FNP found 
in only a few samples. The immunoassays are much less sensi- 
tive to FNP metabolites with only the SBENZ assay being able 
to detect as many as 37% of the GC-MS positive samples. The 
relative sensitivities of the assays for the detection of FNP in- 
gestion is GC-MS > SBENZ > TDx for both urine and serum 
samples. All three assays produce similar excretion patterns 
and can be used for the analysis of urine samples. In general, 
the GC-MS assay, which detects 7-amino-FNP in serum and 
urine, is the best method to determine if a subject has ingested 
a single dose of flunitrazepam. 
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Figure 1. A typical urinary excretion profile from a subject (B) administered a single 2-mg dose of FNP. TDx and SBENZ immunoassay results (ng/mL) com- 
pared to 7-amino-FNP concentration (ng/mL) by GC-MS. 
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